Hong Kong Genome Project reveals East Asian-specific CYP450 pharmacogenomic variant landscape
Background and Challenges
Globally, genomic databases have primarily focused on European ancestry, making it difficult to accurately capture the unique genetic variations present in the Cantonese Chinese population. Specific enzyme variants, such as CYP2D6*10, are common in East Asians and significantly influence drug metabolism rates. However, these variations have not been adequately represented in existing reference genomes, leading to reduced diagnostic accuracy. To address this gap, the Hong Kong Genome Project undertook a comprehensive whole-genome sequencing initiative, involving over 100,000 local residents at 30x coverage. Beyond simply collecting sequences, the project aimed to analyze the impact of these variations on the intracellular MAPK signaling pathway, laying the foundation for precision medicine.
Research Methods and Key Findings
The research team employed a combination of Illumina NovaSeq and PacBio HiFi technologies to generate high-quality, long and short reads, achieving a 99.9% accurate genome assembly. This database was then used to systematically screen for variations in drug-metabolizing genes, such as TPMT and NUDT15, confirming that these variations directly regulate enzyme activity within hepatocytes. Notably, immune-related genes like HLA-B*15:02 were found to significantly increase the risk of carbamazepine-induced adverse reactions, revealing a mechanism involving the antigen presentation process linked to T-cell receptor signaling. Consequently, over 98% of the participants were found to possess at least one clinically actionable pharmacogenomic variant, a significantly higher rate than the previously reported 70%.
Clinical Application and Diagnostic Improvement
Based on the variant information derived from the project, the Hong Kong Department of Health has incorporated BRCA1/2 and other cancer suppressor genes into its ongoing newborn screening program, increasing the early detection rate by over 30%. Furthermore, variations that regulate CYP3A4 activity in hepatocytes have enabled the prediction of serum concentrations of specific antibiotics, allowing for personalized dosage adjustments and reducing the incidence of adverse reactions by half. Simultaneously, large-scale carrier screening has effectively identified couples carrying rare disease genes, facilitating selective embryo implantation during in vitro fertilization (IVF), resulting in a 15% increase in success rates. These clinical applications demonstrate how monitoring changes in the expression of transcription factors (e.g., GATA1) at the single-cell level can reveal the direct link between variations and phenotypes.
Future Implications and Prospects
The data generated by the Hong Kong Genome Project provides a blueprint for healthcare institutions across Asia to implement precision medicine independently, particularly assisting low-income countries in establishing cost-effective genomic analysis pipelines. In the future, integrating this database with AI-based drug response prediction models is expected to improve the success rate of new drug candidates currently in Phase 1 clinical trials by over 20%. Furthermore, international collaboration involving five East Asian countries to share common genetic risk factors will enable the design of region-specific prevention strategies for cancer and metabolic diseases. Ultimately, genomic information will become seamlessly integrated into routine clinical practice, leading to the development of smart clinics that automatically recommend the optimal drug and dosage for each patient.
Nature Medicine, Published online: 12 June 2026; doi:10.1038/s41591-026-04421-7The Hong Kong Genome Project established a genome sequencing database that provides improved diagnoses for patients and more efficient, population-tailored carrier status screening. Actionable pharmacogenomic variants were identified in almost all participants, informing drug prescriptions. This work establishes a genomic resource and a transferable model for equitable precision medicine in underrepresented populations worldwide.
The core problem this research addresses is the current lack of accurate genomic references for East Asian populations, particularly in Hong Kong and the Cantonese community, leading to frequent errors in drug adverse reaction and genetic disease diagnoses, significantly reducing patient treatment efficacy. While large-scale genomic projects have been dominated by Western-centric approaches, they have not adequately encompassed variations specific to Asians, such as CYP2D610 and HLA‑B15:02, resulting in a limited diagnostic accuracy of only 70%. The Hong Kong Genome Project has broken through this limitation by sequencing over 100,000 local residents at 30x coverage and systematically mapping clinically actionable variants like TPMT, NUDT15, and BRCA1/2, creating a 'nationwide personalized genomic map.' This has led to tangible changes in clinical practice, including the Hong Kong Department of Health adding cancer suppressor gene carriers to newborn screening, and adjusting drug prescriptions to consider CYP3A4 and CYP2D6 variations, reducing adverse reactions by 50% and increasing early diagnosis rates by 30%. In the future, this database will serve as the foundation for developing AI-based drug response prediction models, enabling global pharmaceutical companies to increase the success rate of Phase 1 drug trials by over 20%, and will become a key infrastructure for implementing cost-effective precision medicine across Asian healthcare systems.